Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathing new life: rehab program aims to ease lingering symptoms after blood clots in lungs

NCT ID NCT05015153

Symptom relief Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 3-month pulmonary rehabilitation program (20 sessions of exercise and education) can improve quality of life and reduce breathlessness in people who have had a pulmonary embolism. Researchers will enroll 112 adults who still have symptoms at least 3 months after starting blood thinners. The goal is to see if this approach, already used for other lung diseases, can help patients feel better and breathe easier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pulmonary rehabilitation (exercise and education program)
What this could lead to
If it works, this could establish pulmonary rehabilitation as a standard treatment to improve quality of life and reduce breathlessness after a pulmonary embolism.
What could go wrong
This is a relatively small, early-stage trial with 112 participants. The benefits seen in previous small studies may not hold up, and the program requires significant time commitment from patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 112 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Patient treated with at least 3 months and up to 8 months of anticoagulation for symptomatic EP diagnosed according the ESC and ACCP guidelines. * Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q7+8 (dyspnea) and Q4 (impact of daily life) are ≥ 10%. Exclusion Criteria: * Presence of CTEPH according to international guidelines * Patients treated for acute PE with anticoagulants for more than 8 months * Active cancer or in remission for less than two years * Dyspnea post - COVID due to parenchymal injuries * Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae. * Physical or psychological inability to undertake PR * Isolated or more distal segmental PE * Neuro-muscular disease with PR contraindication. * Cardiac insufficiency (unstable coronary artery disease) * Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension) * Chronic dyspnea MMRC ≥ 2 before PE * Cardiac or respiratory rehabilitation in the previous year * Indication to urgent PR within 6 months at the time of inclusion * Life expectancy of less than 12 months * Inability to give consent * Patient under guardianship or curatorship * Patient deprived of liberty by an administrative or judicial decision * Patient has not social security affiliation or who don't beneficiary of such social security

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyspnea pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary embolism Quality of life and dyspnea

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHBS Lorient

    RECRUITING

    Lorient, 56100, France

  • CHU Angers

    RECRUITING

    Angers, 49100, France

  • CHU Brest

    RECRUITING

    Brest, France, 29609, France

  • CHU Saint-Etienne

    RECRUITING

    Saint-Etienne, 42055, France

  • CHU de Grenoble

    RECRUITING

    Grenoble, 38048, France

  • Hegp (Ap-Hp)

    RECRUITING

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.